CD274 and neoplasm: Exploratory biomarker analyses suggest an association of clinical response to immune checkpoint inhibitors (ICIs) with the presence of stromal tumor-infiltrating lymphocytes (TILs), CD8 + T cells, and PD-L1 expression, but these associations have yet to demonstrate clinical utility9.